TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of a non-hematologic (non-myeloid) malignancy~* Scheduled to receive chemotherapy; chemotherapy may be given for adjuvant, neoadjuvant, curative, or palliative intent~* Scheduled to receive the first dose of pegfilgrastim (Neulasta®) to ameliorate chemotherapy-induced neutropenia~* Creatinine ≤ 1.5 times upper limit of normal~* Able to understand English~* More than 6 months since prior surgery on the heart~Exclusion Criteria:~* Pregnant or nursing~* Clinical evidence of active gastrointestinal bleeding, prior gastrointestinal bleeding, or gastric or duodenal ulcers~* Allergy to naproxen~* Prior development of the triad of asthma, rhinitis, and nasal polyps after taking acetylsalicylic acid (aspirin) or other NSAIDs~* Concurrent nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen, or any product containing naproxen (e.g., Naprosyn, EC-Naprosyn, Anaprox, Anaprox-DS, Naprosyn suspension, or Aleve), on a regular basis~* Concurrent steroids on a regular basis~* Concurrent prescription or non-prescription medications for preexisting chronic pain; concurrent cardioprotective doses (≤ 325 mg/day) of aspirin allowed~* Concurrent therapeutic doses of warfarin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Naproxen (Type: EXPERIMENTAL): Patients receive oral naproxen twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing for 5-8 days.
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive an oral placebo twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing for 5-8 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects ≥ 18 years of age and in Bulgaria only ≤ 70 years of age~* Subjects hospitalized with CAP with a severity that requires IV antibiotic treatment for at least 7 days~* The presence of fever (within 24 hours before randomization)~Exclusion Criteria:~* Any concomitant condition that, in the opinion of the investigator, would preclude an evaluation of a response or make it unlikely that the contemplated course of therapy could be completed (eg, life expectancy \<30 days).~* Hospitalization within 14 days before the onset of symptoms.~* Residence in a long-term care facility or nursing home ≥14 days before the onset of symptoms.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of DHA on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 75 years~* Obese patients with Body Mass Index between 30 and 35~* Patients who, regardless of their inclusion in this study, are going to follow the standardized weight-loss programme (PronoKal® Method)~* Patients who agree to participate and sign the Informed Consent form~Exclusion Criteria:~* Treatment with Omega-3 fatty acid supplements for other reasons during the month prior to inclusion in the trial~* Treatment with acetylsalicylic acid (ASA), non-steroidal anti-inflammatory drugs (NSAIDS), corticoids or thiazolidinedione antidiabetic drugs (glitazones)~* Pregnant or nursing patients~* Haemopathy, including clotting disorders~* Treatment with dicoumarin anticoagulants (Sintrom®)~* Cancer or a history of cancer who have not received the oncologist's release~* Type 1 or type 2 diabetes mellitus~* Immune disorders (rheumatoid arthritis, lupus, etc.) and/or inflammatory disease (ulcerative colitis, Crohn's disease, etc.) that may alter the biological markers of inflammation~* Patients not expected to attend monitoring visits

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- omega-3 DHA (Type: ACTIVE_COMPARATOR): Patients in this group will receive 500 mg/day supplement of DHA omega-3 fatty acid in capsule form, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme.
- Control (Type: PLACEBO_COMPARATOR): Patients in control group will receive an placebo capsule, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Depression~* SSRI-treated~Exclusion Criteria:~* Bipolar disorder~* Serotonin-norepinephrine reuptake inhibitor (SNRI) or bupropion treatment~* Treatment-resistant depression~* Seizure disorder~* Bulimia or anorexia nervosa~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Wellbutrin first, then Placebo (Type: EXPERIMENTAL): Subjects randomly assigned to the Wellbutrin then Placebo group will receive 100mg BID of Wellbutrin at the first visit following intake (Week 0).Subjects will be increased to 150mg Wellbutrin BID at Week 1 unless moderate/severe side effects are reported. If subject and rater classify 1+ symptom as severe or 2+ symptoms as moderate, subject will continue on 100mg of bupropion qAM. If subject and rater classify 1+ symptom as moderate or 2+ mild as moderate, subject will continue on Wellbutrin 100mg BID. At Week 4, subjects will cross-over to placebo and will continue to take placebo until Week 8.
- Placebo first, then Wellbutrin (Type: EXPERIMENTAL): Subjects randomly assigned to the Placebo then Wellbutrin group will receive placebo until Week 4 when they will cross-over to active drug. At Week 4, subjects will be assigned 100mg Wellbutrin BID. At Week 5, Subjects will be increased to 150mg Wellbutrin BID unless moderate/severe side effects are reported. If subject and rater classify 1+ symptom as severe or 2+ symptoms as moderate, subject will continue on 100mg of Wellbutrin qAM. If subject and rater classify 1+ symptom as moderate or 2+ mild as moderate, subject will continue on bupropion 100mg BID. Subject will continue on the assigned dosage until Week 8 of study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Males and Females aged 40-80 with a confirmed diagnosis of sporadic Inclusion Body Myositis~Exclusion Criteria:~* Unable to walk at least 3 meters without assistance from another person~* Use of oral beta agonists, oral corticosteroids, androgens or androgen inhibitors, or intravenous gamma globulin in the last 6 months~* patients with a history or presence of renal impairment and/or liver disease~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BYM338 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The participant was a man or woman ≥18 years of age.~* The participant had read, signed, and dated an informed consent form (ICF) prior to any study procedures being performed.~* At the time of enrolment, the participant had been scheduled via written documentation to undergo an ICA for the assessment of CAD.~* The participant had undergone a clinically indicated SPECT OR the participant was willing to undergo SPECT MPI for the purposes of the clinical study.~* The participant was male or was a nonpregnant, nonlactating female who was either surgically sterile or was post-menopausal.~* The participant was able and willing to comply with all study procedures as described in the protocol.~Exclusion Criteria:~* Participants who were pregnant, may possibly be pregnant, or wish (including their partners) to became pregnant during the study period, or were lactating.~* Participants who were unable to undergo all of the imaging procedures.~* Participants who had an established diagnosis of CAD as confirmed by any of the following:~  1. Previous myocardial infarction (MI);~ 2. Previous cardiac catheter angiography showing ≥50% stenosis;~ 3. Previous coronary revascularisation, such as percutaneous coronary intervention (PCI), thrombolysis or coronary artery bypass graft (CABG) placement.~* Participants incapable of undergoing either exercise or pharmacological cardiac stress testing.~* Participants who had a current illness or pathology that, in the opinion of the investigator, would pose a significant safety risk for the participant during cardiac stress testing.~* Documented history of heart failure and/or cardiomyopathy and/or prior LV ejection fraction (LVEF) \<50%).~* Participants scheduled for or planning to undergo any cardiac interventional procedures between enrolment and ICA.~* Participants undergoing evaluation for heart transplantation or with history of heart transplantation.~* Participants enrolled in another clinical study within the 30 days prior to being enrolled in this study or scheduled to participate in another clinical study during the 7-day follow-up period of this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Flurpiridaz PET MPI (following off-study SPECT MPI)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients referred to undergo a clinically-indicated regadenoson-stress myocardial perfusion imaging at Rush University Medical Center~* Stage IV or V chronic kidney disease (GFR \< 30, hemodialysis, and/or peritoneal dialysis).~Exclusion Criteria:~* Patient refusal to participate~* Known allergic reaction to aminophylline.~* Pre-existing headache or acute/subacute GI illness with symptoms of diarrhea, abdominal discomfort, nausea or vomiting.~* Any contraindication to aminophylline: hypotension, unstable cardiac arrhythmias and acute coronary symptoms.~* Uncontrolled seizure disorder defined as more than 2 seizure episodes in the past 12 months or any seizure in the past week.~* Pregnant or breast-feeding women.~* Patients receiving anti-platelet agent dipyridamole (Persantine® or Aggrenox®).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aminophylline (Type: EXPERIMENTAL): 75 mg of intravenous aminophylline.
- Placebo (Type: PLACEBO_COMPARATOR): Matching 0.9 Normal Saline (sterile salt water)administered intravenously.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of ulcerative colitis, inflammatory bowel disease unclassified, indeterminate colitis, or Crohn's disease;~* Major colorectal surgery, defined as surgery requiring an abdominal incision. Both open and laparoscopic procedures are eligible. Urgent and elective procedures are eligible;~* Corticosteroid therapy within 12 months of surgery;~* Able and willing to comply with all protocol procedures for the planned duration of the study~* Able and willing to understand, sign and date an informed consent document, and authorize access to protected health information.~Exclusion Criteria:~* Patients with hypotension (systolic \< 90 mm Hg or diastolic \< 50 mm Hg) in the preoperative area~* Patients having emergency surgery~* Children \< 18 or adults \> 75 years of age~* Pregnant patients~* Patients who have suffered prior hemodynamic complications of steroid withdrawal~* Other major physical or major psychiatric illness, including alcohol or substance addiction, within the last 6 months that in the opinion of the investigator would affect the patient's ability to complete the trial.~* Any condition or situation that, in the opinion of the investigator, would prevent proper evaluation of the safety or efficacy of the different steroid doses according to the study protocol~* Patients on steroids without inflammatory bowel disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Hydrocortisone High Dose (Type: ACTIVE_COMPARATOR): Intervention: Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
- Hydrocortisone Low Dose (Type: EXPERIMENTAL): Intervention: 1/3 Intravenous equivalent dose (IVED) at surgical incision, followed by 1/3 IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD) 1, followed by 1/6 IVED every 8 hours on POD 2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of GH001 in Depression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has a body mass index (BMI) in the range of 18.5 and 35.0 kg/m2 (inclusive);~* Meets the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria for single-episode major depressive disorder (MDD) or recurrent MDD, without psychotic features confirmed by the Mini-International Neuropsychiatric Interview (MINI);~* Treatment-Resistant Depression as evaluated by the Antidepressant Treatment History Form - Short Form (ATHF-SF);~* Has outpatient status at screening and enrolment visits;~Exclusion Criteria:~* Has a current or prior diagnosis of a psychiatric comorbidity that renders the patient unsuitable for the study according to a study psychiatrist or registered psychologist;~* Has received any investigational medication within the last 1 month;~* Has a current medically significant condition (e.g., severe infection) or has a history of a medically significant condition (e.g., medical history of seizure, uncontrolled hypertension, uncontrolled diabetes, severe cardiovascular disease, hepatic or renal failure, etc.) that renders the patient unsuitable for the study according to the medical supervisor's judgment;~* Takes any medication or other substance that renders the patient unsuitable for the study according to the medical supervisor's judgment;~* Has a clinically significant abnormality in physical examination, vital signs, ECG, or clinical laboratory parameters, which renders the patient unsuitable for the study according to the medical supervisor's judgment;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Phase 1 (Part A): GH001 dose A (Type: EXPERIMENTAL): None
- Phase 1 (Part A): GH001 dose B (Type: EXPERIMENTAL): None
- Phase 2 (Part B): GH001 Individualized Dosing Regimen (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Local Anesthetic Properties of Neosaxitoxin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy males with the abilities to understand and respond the tests to perform~Exclusion Criteria:~* Use of any oral analgesics at least ten days before the study~* Drugs abuse history~* Showing at the clinical examination any signal of psychiatric disorder

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Development of Ursodeoxycholic Acid 300 mg at Hospital Das Clinicas of the University of São Paulo School of Medicine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Primary biliary cholangitis (PBC) was diagnosed when at least two of the following three criteria: histologically proven early stage PBC; positive Anti-mitochondrial antibody (AMA) (titer \>1:40) and alkaline phosphatase \>1.5 times upper limit of normal at any time since diagnosis.~* Patients had to be on ursodeoxycholic acid for at least 6 months.~* Patients should be able to understand and ready to sign the informed consent form.~Exclusion Criteria:~* Patients not adherent to treatment with reference medicine.~* Known intolerance to the study drugs.~* Patients who withdrew their agreement.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- capsule (Type: EXPERIMENTAL): pharmaceutical form: capsule ursodeoxycholic acid 300 mg 13-15mg/kg day 3 months
- tablet (Type: EXPERIMENTAL): pharmaceutical form: tablet ursodeoxycholic acid 300 mg 13-15mg/kg day 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of V70P5 Revaccination Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 13.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female children that have previously participated in the V70P5 study in Finland.~Exclusion Criteria:~* Any condition which in the opinion of the investigator may interfere with the evaluation of the study objectives.

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 96 Months
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): None
- Group 2 (Type: EXPERIMENTAL): None
- Group 3 (Type: EXPERIMENTAL): None
- Group 4 (Type: EXPERIMENTAL): None
- Group 5 (Type: EXPERIMENTAL): None
- Group 6 (Type: EXPERIMENTAL): None
- Group 7 (Type: EXPERIMENTAL): None
- Group 8 (Type: EXPERIMENTAL): None
- Group 9 (Type: EXPERIMENTAL): None
- Group 10 (Type: EXPERIMENTAL): None
- Group 11 (Type: EXPERIMENTAL): None
- Group 12 (Type: EXPERIMENTAL): None
- Group 13 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete